Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

60.70
Delayed Data
As of May 24
 +1.40 / +2.36%
Today’s Change
45.45
Today|||52-Week Range
71.60
+2.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$95.9B

Company Description

AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company's focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on April 10, 2012 and is headquartered in North Chicago, IL.

Contact Information

AbbVie, Inc.
1 North Waukegan Road
North Chicago Illinois 60064-6400
P:(847) 932-7900
Investor Relations:
(847) 935-2211

Employees

Shareholders

Other institutional36.25%
Mutual fund holders33.98%
Individual stakeholders0.10%

Top Executives

Richard A. GonzalezChairman & Chief Executive Officer
Azita Saleki-GerhardtSenior Vice President-Operations
William J. ChaseChief Financial Officer & Executive Vice President
Michael E. SeverinoChief Scientific Officer & Executive VP
Karen HaleVP, Chief Compliance & Ethics Officer